JP2017511377A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511377A5 JP2017511377A5 JP2017501145A JP2017501145A JP2017511377A5 JP 2017511377 A5 JP2017511377 A5 JP 2017511377A5 JP 2017501145 A JP2017501145 A JP 2017501145A JP 2017501145 A JP2017501145 A JP 2017501145A JP 2017511377 A5 JP2017511377 A5 JP 2017511377A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- disease
- compounds
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 206010001897 Alzheimer's disease Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
Claims (10)
- トラミプロゼート、式Ｉ
- 前記化合物が、トラミプロゼートおよび式
- 式
- トラミプロゼート、式Ｉ
- 前記化合物が、トラミプロゼートおよび式
- 式
- 前記使用が、アルツハイマー病に関連する認知機能低下の低減のためのものである、請求項１〜３のいずれか１項に記載の組成物または請求項４〜６のいずれか１項に記載の医薬組成物。
- アルツハイマー病に罹患している患者のＡｐｏＥ４状態を、該患者がトラミプロゼート、式Ｉ
- 前記化合物が、トラミプロゼートおよび式
- 前記化合物が式
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968595P | 2014-03-21 | 2014-03-21 | |
| US61/968,595 | 2014-03-21 | ||
| PCT/US2015/022058 WO2015143447A2 (en) | 2014-03-21 | 2015-03-23 | Methods for treating neurological disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019012873A Division JP2019065044A (ja) | 2014-03-21 | 2019-01-29 | 神経疾患を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511377A JP2017511377A (ja) | 2017-04-20 |
| JP2017511377A5 true JP2017511377A5 (ja) | 2018-03-29 |
| JP6588962B2 JP6588962B2 (ja) | 2019-10-09 |
Family
ID=54145492
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501145A Active JP6588962B2 (ja) | 2014-03-21 | 2015-03-23 | 神経疾患を治療するための方法 |
| JP2019012873A Withdrawn JP2019065044A (ja) | 2014-03-21 | 2019-01-29 | 神経疾患を治療するための方法 |
| JP2020066670A Withdrawn JP2020109123A (ja) | 2014-03-21 | 2020-04-02 | 神経疾患を治療するための方法 |
| JP2022131705A Pending JP2022159555A (ja) | 2014-03-21 | 2022-08-22 | 神経疾患を治療するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019012873A Withdrawn JP2019065044A (ja) | 2014-03-21 | 2019-01-29 | 神経疾患を治療するための方法 |
| JP2020066670A Withdrawn JP2020109123A (ja) | 2014-03-21 | 2020-04-02 | 神経疾患を治療するための方法 |
| JP2022131705A Pending JP2022159555A (ja) | 2014-03-21 | 2022-08-22 | 神経疾患を治療するための方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10471029B2 (ja) |
| EP (2) | EP4289820A3 (ja) |
| JP (4) | JP6588962B2 (ja) |
| KR (2) | KR102645633B1 (ja) |
| CN (1) | CN106170563A (ja) |
| AU (1) | AU2015230972B2 (ja) |
| CA (1) | CA2941415A1 (ja) |
| DK (1) | DK3119911T3 (ja) |
| ES (1) | ES2960625T3 (ja) |
| FI (1) | FI3119911T3 (ja) |
| HR (1) | HRP20231172T1 (ja) |
| HU (1) | HUE063369T2 (ja) |
| LT (1) | LT3119911T (ja) |
| PL (1) | PL3119911T3 (ja) |
| PT (1) | PT3119911T (ja) |
| RS (1) | RS64744B1 (ja) |
| SI (1) | SI3119911T1 (ja) |
| WO (1) | WO2015143447A2 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017044840A1 (en) * | 2015-09-10 | 2017-03-16 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular patient population |
| US20200196637A1 (en) * | 2016-07-13 | 2020-06-25 | Mitos Co., Ltd. | Composition for prevention or treatment of mild cognitive impairment or dementia containing hydrogen as active ingredient |
| CN108623501B (zh) * | 2017-03-21 | 2022-04-19 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸衍生物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| CN110668980A (zh) * | 2018-07-03 | 2020-01-10 | 浙江京新药业股份有限公司 | 一种2-取代的高牛磺酸衍生物 |
| SG11202100767XA (en) * | 2018-08-01 | 2021-02-25 | Alzheon Inc | Methods for treating neurodegenerative disorders |
| AU2019314323A1 (en) * | 2018-08-01 | 2021-03-18 | Alzheon, Inc. | Sulfopropanoic acid derivatives for treating neurodegenerative disorders |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| CN114269949A (zh) * | 2019-06-17 | 2022-04-01 | 阿尔泽恩股份有限公司 | 用于治疗神经变性病症的方法 |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| WO2023212289A1 (en) | 2022-04-28 | 2023-11-02 | Alzheon, Inc. | Tramiprosate for treating apoe4-related diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| ES2148116T1 (es) * | 1992-10-13 | 2000-10-16 | Univ Duke | Metodos de detectar la enfermedad de alzheimer. |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20060079578A1 (en) * | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| SG145784A1 (en) | 2003-08-11 | 2008-09-29 | California Inst Of Techn | Microfluidic large scale integration |
| CA2666246C (en) * | 2006-10-12 | 2013-12-31 | Bellus Health (International) Limited | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| CA2670418A1 (en) * | 2006-11-24 | 2008-05-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's |
| WO2012006329A2 (en) * | 2010-07-06 | 2012-01-12 | Genomind, Llc | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| BR112013003847A8 (pt) | 2010-08-19 | 2017-12-26 | Buck Institute For Age Res | métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados |
| WO2014182631A1 (en) | 2013-05-06 | 2014-11-13 | Baxter International Inc. | Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g |
| TWI705824B (zh) * | 2014-02-08 | 2020-10-01 | 美商建南德克公司 | 治療阿茲海默症之方法 |
| WO2017044840A1 (en) | 2015-09-10 | 2017-03-16 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular patient population |
| US20180250249A1 (en) | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
-
2015
- 2015-03-23 WO PCT/US2015/022058 patent/WO2015143447A2/en active Application Filing
- 2015-03-23 ES ES15764560T patent/ES2960625T3/es active Active
- 2015-03-23 KR KR1020227033161A patent/KR102645633B1/ko active IP Right Grant
- 2015-03-23 HR HRP20231172TT patent/HRP20231172T1/hr unknown
- 2015-03-23 DK DK15764560.7T patent/DK3119911T3/da active
- 2015-03-23 SI SI201531967T patent/SI3119911T1/sl unknown
- 2015-03-23 KR KR1020167027090A patent/KR102448386B1/ko active IP Right Grant
- 2015-03-23 RS RS20230993A patent/RS64744B1/sr unknown
- 2015-03-23 US US15/127,565 patent/US10471029B2/en active Active
- 2015-03-23 EP EP23189240.7A patent/EP4289820A3/en active Pending
- 2015-03-23 PL PL15764560.7T patent/PL3119911T3/pl unknown
- 2015-03-23 PT PT157645607T patent/PT3119911T/pt unknown
- 2015-03-23 AU AU2015230972A patent/AU2015230972B2/en active Active
- 2015-03-23 JP JP2017501145A patent/JP6588962B2/ja active Active
- 2015-03-23 FI FIEP15764560.7T patent/FI3119911T3/fi active
- 2015-03-23 LT LTEPPCT/US2015/022058T patent/LT3119911T/lt unknown
- 2015-03-23 CA CA2941415A patent/CA2941415A1/en active Pending
- 2015-03-23 HU HUE15764560A patent/HUE063369T2/hu unknown
- 2015-03-23 EP EP15764560.7A patent/EP3119911B1/en active Active
- 2015-03-23 CN CN201580015086.8A patent/CN106170563A/zh active Pending
-
2019
- 2019-01-29 JP JP2019012873A patent/JP2019065044A/ja not_active Withdrawn
- 2019-09-13 US US16/570,487 patent/US20200101031A1/en not_active Abandoned
-
2020
- 2020-04-02 JP JP2020066670A patent/JP2020109123A/ja not_active Withdrawn
-
2022
- 2022-07-29 US US17/877,380 patent/US20230087041A1/en active Pending
- 2022-08-22 JP JP2022131705A patent/JP2022159555A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511377A5 (ja) | ||
| JP2019218375A5 (ja) | ||
| JP2020097577A5 (ja) | ||
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| JP2019516739A5 (ja) | ||
| JP2016536286A5 (ja) | ||
| JP2016521119A5 (ja) | ||
| JP2015024998A5 (ja) | ||
| JP2016501221A5 (ja) | ||
| JP2017518334A5 (ja) | ||
| JP2017528503A5 (ja) | ||
| JP2009501202A5 (ja) | ||
| JP2014500861A5 (ja) | ||
| JP2015501783A5 (ja) | ||
| JP2017514910A5 (ja) | ||
| JP2016516074A5 (ja) | ||
| JP2013507415A5 (ja) | ||
| JP2016522254A5 (ja) | ||
| JP2019529514A5 (ja) | ||
| JP2012504133A5 (ja) | ||
| FI3119911T3 (fi) | Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa | |
| JP2018529698A5 (ja) | ||
| EP3932907A3 (en) | Dextromethorphan analogs and combinations of deuterated dextromethorphan and nortriptyline for use in treating agitation and/or aggression | |
| JP2010521516A5 (ja) | ||
| BR112012016460A2 (pt) | diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica. |